A sensitive and specific NGS‐based assay used to detect MRD in a FLT3‐ITD+ R/R AML patient subset who achieved morphologic CR with gilteritinib in the CHRYSALIS study demonstrated a relationship between FLT3‐ITD mutation burden and overall survival (OS).9 Here, FLT3 is linked to acute myeloid leukemia.